Table 3.
Comparison of the incidence of common adverse events (any grade) between camrelizumab combination and chemotherapy.
| Common adverse event | Camrelizumab combination (incidence rate) | Chemotherapy (incidence rate) |
|---|---|---|
| Any grade | Any grade | |
| Reactive capillary hyperplasia | 78% | <1% |
| Elevated aspartate aminotransferase | 47% | 33% |
| Elevated alanine aminotransferase | 48% | 40% |
| Anemia | 34% | 27% |
| Elevated serum bilirubin | 11% | 5% |
| Leukopenia | 91% | 78% |
| Hypothyroidism | 11% | 0% |